Management Team

Stephen A. Bollinger
Helen Marie Nugent, Ph.D.
Laurie A. Ridener, R.A.C.
Jack Harvey, M.S.
Glenn T. Kanner
Margaret E. O'Toole
Molly E. Rosano, M.B.A.
John L. Wilson

Stephen A. Bollinger
President & COO

Mr. Bollinger assumed the role of President and Chief Operating Office at Pervasis Therapeutics in June 2005. Prior to Pervasis, Mr. Bollinger was a founder and the Chief Operating Officer of Angiolink Corporation, which was a privately held medical device company, with responsibilities for overall operations, from 2000 to 2004, and sold the company to Medtronic Corporation in fall of 2004. From 1997 to 1999 Mr. Bollinger was the Vice President of Research, Development, and Operations for Byron Medical and held overall responsibility for corporate operations. He sold the company to Mentor Corporation in 1999. From 1991 to 1997, Mr. Bollinger has held positions at Mentor Corporation, American Hydro-Surgical Instruments, and Deknatel, in a variety of roles ranging from Sales to Product Development and Marketing Management.

Mr. Bollinger served as an artillery officer in the United States Army from 1987 to 1991, and during his service he led and supervised reconnaissance teams into combat during Operation Desert Storm. In 1991, he was awarded the Bronze Star Medal for exceptional meritorious service during combat. Also during his service, he graduated from the United States Army Airborne and Ranger Schools. Mr. Bollinger currently holds six medical patents. He received his M.B.A. from Oklahoma City University and is a graduate of the United States Military Academy West Point with a B.S. in mechanical engineering.

[ back to top ]

Helen Marie Nugent, Ph.D.
Co-Founder and Vice President, Research and Development

Dr. Nugent is a Founder and Vice President, Research and Development, at Pervasis Therapeutics and also holds a Research Affiliate position in the Harvard-MIT Division of Health Sciences and Technology. Dr. Nugent received a B.S. degree in chemistry from Merrimack College and both M.A. and Ph.D. degrees in Organic Chemistry from Brandeis University. Her doctoral thesis concentrated on the synthesis of novel organometallic polymers. She continued her work in material science by completing a one-year fellowship at the Institute for Polymers and Organic Solids at the University of California, Santa Barbara. Dr. Nugent joined MIT as a postdoctoral fellow and performed research on tissue engineered endothelial cells, which resulted in numerous peer-reviewed publications and abstract presentations.

Dr. Nugent has more than 8 years experience in the biotechnology industry directing and performing critical research and developmental work and over 10 years experience in vascular and endothelial biology. She previously held positions at Reprogenesis, Inc. and its successor; Curis, Inc. Dr. Nugent has been the recipient of a National Science Foundation Research Fellowship and served as the Principal Investigator on a National Institutes of Standards and Technology Advanced Technology Program Award.

[ back to top ]

Laurie A. Ridener, R.A.C.
Senior Director, Clinical and Regulatory Affairs

Ms. Ridener joined Pervasis Therapeutics in March 2006 and serves as Senior Director, Clinical and Regulatory Affairs. Ms. Ridener has over 20 years in the biotech/pharmaceutical and medical device industries. Prior to Pervasis, Ms. Ridener was the Senior Manager for US Regulatory Affairs in the Metabolic Endocrinology Therapeutic Division at Serono, Inc., the fourth largest biotech company worldwide, where she provided strategic and tactical expertise to local and global drug product development teams to ensure compliance with regulatory requirements while meeting marketing objectives. Previous to Serono, Ms. Ridener was the Director of Clinical and Regulatory Affairs at Biolink Corp., a small start-up manufacturer of a vascular access medical device, where she was responsible for all regulatory activities and for managing multiple domestic and international clinical research programs including a 4-center international pilot study and a domestic 12-center pivotal study. Currently, Ms. Ridener is a course facilitator for Regulatory and Compliance Issues for Boston University School of Medicine’s Graduate Certificate Program in Clinical Investigation. Ms. Ridener received her B.A. in Philosophy from the University of Colorado.

[ back to top ]

Jack Harvey, M.S.
Director, Manufacturing

Mr. Harvey joined Pervasis Therapeutics in December 2005 and serves as Director, Manufacturing. Mr. Harvey oversees the manufacturing of Vascugel® for clinical evaluation and the development and optimization of the manufacturing process. Mr. Harvey has over 20 years of experience in the development and manufacturing of Cell Therapy/Tissue Engineering products. He has held positions with technical and organizational leadership responsibilities, supporting multiple INDs covering therapies in Phase I-II clinical trials. Mr. Harvey participated in the development of numerous products from bench scale processes through manufacturing for Phase II human clinical trials at BioHybrid Technologies, CytoTherapeutics, and Bioheart. During his career he has developed a broad range of expertise in process/product development, and manufacturing for cell and tissue based products. Mr. Harvey is a graduate from Harvard University and earned a Master’s degree in Public Health from Boston University.

[ back to top ]

Glenn T. Kanner
Director, Engineering

Mr. Kanner joined Pervasis Therapeutics in November 2006 and serves as Director, Engineering. He has over 20 years experience in the development of medical devices, in vitro diagnostic systems and aerospace technologies. Before joining Pervasis Therapeutics, Mr. Kanner was Manager of Research and Development for Medtronic Vascular. He assumed this role following Medtronic’s acquisition of Angiolink Corporation where, from 2000 to 2004, he led the team responsible for development of the company’s flagship vascular closure product. In addition to active participation in new product development, design and validation, Mr. Kanner has supported several medical device PMA and 510(k) submissions and created the computer model used in development of the successful Mars Pathfinder landing system. He has held positions at Mentor Corporation, ILC Dover and Ohmeda. Mr. Kanner has been assigned eight U.S. patents. He is a graduate of the University of Akron where he received a B.S. in Mechanical Engineering and a B.A. in Chemistry.

[ back to top ]

Margaret E. O’Toole
Director, Business Administration

Ms. O’Toole joined Pervasis Therapeutics in March 2005 and serves as Director, Business Administration. She was initially brought on board to establish the company infrastructure and is now responsible for business management and daily operations. Her responsibilities include human resources, finance, public relations, and website development. Ms. O’Toole has over 14 years of experience in business start-ups ranging from hi-tech engineering to magazine publishing. Prior to Pervasis, she was the Operations Manager for Reputation Technologies; a Massachusetts based hi-tech start-up acquired by Security Source, Inc. Ms. O’Toole previously held management positions in corporate communications, marketing, and proposal management with Synetics, Inc.; acquired by ACS, Inc., and Elephant Engineering; acquired by Syntronics, LLC. Ms. O’Toole was the Editorial Director of Shaadi Style Magazine and a marketing consultant for The Wonder Factory, a Virginia based children’s museum. Ms. O’Toole received her B.A. in Literature from Carnegie Mellon University.

[ back to top ]

Molly E. Rosano, M.B.A.
Director, Clinical Affairs

Ms. Rosano joined Pervasis Therapeutics in March of 2007 and serves as Director, Clinical Affairs. She has eighteen years of experience in various positions in the pharmaceutical and biotechnology industry. Prior to Pervasis, Ms. Rosano was the Associate Director of Clinical Project Management at Sepracor, Inc., where she served in a leadership role in the strategic planning, development and execution of clinical programs for several therapeutic areas. Her experience spans all phases of clinical development and post-marketing research, and she has initiated and managed clinical trials in North America, Europe, and Asia. She previously held positions in clinical research, market research, and sales as MORPACE Pharma Group, Astra USA, Boots Pharmaceuticals and Abbott Laboratories. Ms. Rosano has been a panel speaker for the Drug Information Association, Massachusetts Biotechnology Council and various other organizations regarding the execution of large multi-center clinical trials. Ms. Rosano holds a B.S. in Biology from Siena College and an M.B.A. from Regis University.

[ back to top ]

John L. Wilson
Director, Clinical Operations

Mr. Wilson joined Pervasis Therapeutics in January, 2006 and serves as Director, Clinical Operations. Prior to his assumption of duties at Pervasis, Mr. Wilson had been the Director of Sales/Clinical Affairs at the Angiolink Corporation, a privately held medical device start-up company which successfully sold to Medtronic in November of 2004. While there, Mr. Wilson successfully brought in the Pivotal US Clinical Trial leading to issuance of PMA by the FDA. Assuming the role of Global Training Director for Medtronic, Mr. Wilson solidified and integrated the Angiolink device into the Medtronic portfolio of devices until his departure in January 2006. Mr. Wilson was a founder and the Director of Sales at Apis, Inc., a privately held agricultural service business which successfully sold in 2000. Mr. Wilson has held positions at American Hydro-Surgical Instruments, and Deknatel, Pfizer Hospital Products Group in a variety of Sales, Sales Management, and Clinical Roles.

Mr. Wilson served as an infantry officer in the United States Army from 1986 to 1990 stationed in the Federal Republic of Germany (BRD) and is a graduate of The Citadel, The Military College of South Carolina. He holds a B.A. in Modern European History.

[ back to top ]